NEVIRAPINE (nevirapine) by Viatris (2) is non-nucleoside reverse transcriptase inhibitors [moa]. Approved for combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adults, older. First approved in 2019.
Drug data last refreshed 18h ago
Non-Nucleoside Reverse Transcriptase Inhibitors
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Worked on NEVIRAPINE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease
The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs